Orient Bio

Orient Bio Gross Margin

The Gross Margin of Orient Bio (002630.KS) as of Oct 24, 2026 is 17.42 %. In the previous year, Gross Margin was 24.48 % — a change of -28.83% (lower).

Gross Margin

17.42 %

YoY

-28.83%

Last updated:

Gross Margin of Orient Bio is 2026 17.42 % . Gross Margin of Orient Bio was 2025 24.48 % . It decreases by -28.83% lower compared to the previous year.

For Orient Bio, the gross margin of 17.4% is down versus 34.3% a few years ago.

The Orient Bio Gross Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Gross Margin
Date
Gross Margin
Jan 1, 2019
36.51 KRW
Jan 1, 2020
19.10 KRW
Jan 1, 2021
36.96 KRW
Jan 1, 2022
34.30 KRW
Jan 1, 2023
44.81 KRW
Jan 1, 2024
34.22 KRW
Jan 1, 2025
24.48 KRW
Jan 1, 2026
17.42 KRW
The Orient Bio Gross Margin history
YEARGross MarginYoY
17.42 %-28.83%
24.48 %-28.47%
34.22 %-23.63%
44.81 %+30.64%
34.30 %-7.19%
36.96 %+93.54%
19.10 %-47.69%
36.51 %+196.49%
12.31 %+60.36%
7.68 %-48.72%
14.97 %-13.10%
17.23 %+12.75%
15.28 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Orient Bio Stock analysis

What does Orient Bio do? Orient Bio Inc generates revenue through the production and supply of laboratory animals such as mice, rats, guinea pigs, hamsters, SPF rabbits, and beagles. The company also offers CRO services including safety assessments and new drug development, alongside medical and library equipment like barrier systems. Additional income comes from support services such as rodent surgery, laboratory diagnostics, transgenic services, and genetic testing. The firm further provides feeds, reagents, disinfectants, automobile components, power supply equipment, and other machines through its subsidiaries. Orient Bio Inc's primary customers include research institutions, pharmaceutical companies, and medical facilities requiring laboratory animals and specialized services. The company's product segments consist of live animals, CRO services, medical equipment, and ancillary products like feeds and reagents. Subsidiaries contribute to revenue by supplying complementary items such as disinfectants and power supply equipment. The business model leverages a diversified portfolio of biotechnology products and services, targeting both direct research and development needs and ancillary support requirements. Revenue streams are derived from the sale of animals, provision of CRO services, equipment sales, and subsidiary product lines, ensuring steady income across multiple segments. Orient Bio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Orient Bio stock

Gross Margin of Orient Bio is 17.42 % in 2026.

Gross Margin of Orient Bio changed from 24.48 % to 17.42 %, representing a -28.83% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Gross Margin Orient Bio since 2006 – with annual values, charts, and detailed analysis.

Gross Margin measures the percentage of revenue remaining after COGS. Higher gross margins indicate more efficient production and stronger pricing power.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Gross Margin's Orient Bio with sector peers and the industry average to assess whether it is attractive.

To evaluate Gross Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Gross Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Orient Bio

All Key Metrics — Orient Bio